US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.89 ▼-1.02% TSLA $378.69 ▲+2.18% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Articles published by Recursion Pharmaceuticals, Inc.

News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers EXAI RXRX
News headline image
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers EXAI RXRX
News headline image
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Announces Plans to Open New Office in London
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX
News headline image
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RXRX